Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ tyloxapol,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Respiratory Conditions:

    • Pulmonary Surfactant Replacement: Tyloxapol is used in aerosolized form as an adjunctive therapy in the treatment of respiratory distress syndrome (RDS) in premature infants. It helps to improve lung compliance by reducing surface tension within the alveoli and preventing their collapse.
    • Expectorant: Tyloxapol may be used as an expectorant to help loosen and expel mucus from the respiratory tract. It works by decreasing the viscosity of respiratory secretions, making them easier to cough up.
  2. Ophthalmic Conditions:

    • Ophthalmic Surfactant: Tyloxapol is used in ophthalmic preparations to enhance drug solubility and penetration. It is often included in eye drops or ointments to improve the delivery of medications to the eye and increase their bioavailability.
    • Eyelid Cleansing: Tyloxapol-containing solutions may also be used for eyelid hygiene and cleansing. These solutions help remove debris, crusts, and excess oil from the eyelids, contributing to overall eye health.
  3. Other Uses:

    • Industrial Applications: Tyloxapol is sometimes used in industrial settings, such as in cleaning solutions and as a dispersing agent for various substances.
    • Experimental Research: In laboratory settings, tyloxapol may be used in experimental research, particularly in studies related to surfactants, drug delivery systems, and cell culture techniques.
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of tyloxapol,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by tyloxapol,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Streptococcus genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Roseburia genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Bilophila wadsworthia species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
[Ruminococcus] gnavus species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of tyloxapol,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.4 0.4
ADHD 0.2 0.2
Age-Related Macular Degeneration and Glaucoma 0.2 0.2
Allergic Rhinitis (Hay Fever) 0.1 0.1
Allergies 0.1 0.1 0
Allergy to milk products 0.1 0 0
Alzheimer's disease 0.5 1 -1
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0 0.1 0
Ankylosing spondylitis 0.6 0.1 5
Anorexia Nervosa 0.2 -0.2
Antiphospholipid syndrome (APS) 0.9 0.4 1.25
Asthma 0.2 -0.2
Atherosclerosis 0 0.5 0
Atrial fibrillation 0.5 0.5 0
Autism 0.8 1.1 -0.38
Barrett esophagus cancer 0.5 -0.5
benign prostatic hyperplasia 0 0
Bipolar Disorder 0.5 0.2 1.5
Brain Trauma 0.2 -0.2
Carcinoma 0.9 0 0
Celiac Disease 0.5 0.4 0.25
Cerebral Palsy 0.5 0.2 1.5
Chronic Fatigue Syndrome 0.7 0.5 0.4
Chronic Kidney Disease 0.1 0.2 -1
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 1.4 0.2 6
Chronic Urticaria (Hives) 0.5 0.1 4
Coagulation / Micro clot triggering bacteria 0.5 0.7 -0.4
Colorectal Cancer 1.2 1.2
Constipation 0 0.2 0
Coronary artery disease 0.1 0.1
COVID-19 0.6 2.1 -2.5
Crohn's Disease 0.7 0.2 2.5
cystic fibrosis 0.1 0.2 -1
deep vein thrombosis 0.1 0.7 -6
Depression 1.1 0.8 0.38
Dermatomyositis 0.5 0.5
Eczema 0.1 1.4 -13
Endometriosis 0.5 0 0
Epilepsy 0.5 0.5
Fibromyalgia 0.2 0.1 1
Functional constipation / chronic idiopathic constipation 0.5 0.2 1.5
gallstone disease (gsd) 0.1 0.2 -1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.5 -0.5
Generalized anxiety disorder 0.1 0.1
Glioblastoma 0.5 -0.5
Graves' disease 0.2 -0.2
Halitosis 0.5 -0.5
Hashimoto's thyroiditis 0.2 0.4 -1
Hidradenitis Suppurativa 0.8 0.8
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.2 0 0
hyperglycemia 0 0
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 0.5 1 -1
IgA nephropathy (IgAN) 0.1 -0.1
Inflammatory Bowel Disease 1.5 0.7 1.14
Insomnia 0.5 0.2 1.5
Intelligence 0.1 -0.1
Intracranial aneurysms 0 0
Irritable Bowel Syndrome 0.3 0.2 0.5
Liver Cirrhosis 1.1 1.1 0
Long COVID 0.5 0.7 -0.4
Low bone mineral density 0.2 -0.2
Lung Cancer 0 0 0
ME/CFS with IBS 0.5 0.5
ME/CFS without IBS 0.6 0.6
Metabolic Syndrome 1.2 1.1 0.09
Mood Disorders 1.5 0.8 0.88
multiple chemical sensitivity [MCS] 1.4 1.4
Multiple Sclerosis 1.8 0.7 1.57
Multiple system atrophy (MSA) 0 0
Neuropathy (all types) 0.5 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.5 0 0
Obesity 1.1 1.1 0
obsessive-compulsive disorder 0.6 0.1 5
Osteoarthritis 0.5 0 0
Osteoporosis 0.1 0.1
pancreatic cancer 0.5 0.5
Parkinson's Disease 0.9 1.1 -0.22
Polycystic ovary syndrome 0.1 0.3 -2
Psoriasis 0.6 0.2 2
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.2 0.2 5
Rosacea 0 0.2 0
Schizophrenia 0.4 0.2 1
scoliosis 0.4 -0.4
Sjögren syndrome 0.5 0.5
Sleep Apnea 0 0.2 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.5 0.5
Stress / posttraumatic stress disorder 0.2 0.2 0
Systemic Lupus Erythematosus 0.9 0.2 3.5
Tic Disorder 0 0.1 0
Type 1 Diabetes 0.5 0.6 -0.2
Type 2 Diabetes 1.2 0.7 0.71
Ulcerative colitis 0.6 0.6 0
Unhealthy Ageing 0.9 0.2 3.5

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]